Bacillus subtilis Bacteriocin for Broad Gram-Negative Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional bacteriocins derived from gram-positive bacteria exhibit narrow antimicrobial spectra, lacking activity against gram-negative bacteria and fungi, necessitating the development of compounds with broader antimicrobial efficacy.
Innovation Solution
Development of an anti-gram-negative bacterial compound with the amino acid sequence represented by chemical formula 1, produced by Bacillus subtilis, particularly the MT2 strain, which demonstrates antimicrobial activity against both gram-negative bacteria and fungi.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional bacteriocins derived from gram-positive bacteria are used, then antimicrobial activity against gram-positive bacteria is achieved, but antimicrobial activity against gram-negative bacteria is lost
Solution Approach 1:
The patent modifies the amino acid sequence parameters of conventional bacteriocins by substituting specific residues (e.g., replacing hydrophobic residues with hydrophilic ones, or vice versa) to alter the peptide's interaction with different bacterial cell envelopes. This parameter change enables the modified bacteriocin to penetrate both gram-positive and gram-negative bacterial cell walls while retaining activity against gram-positive bacteria.
Solution Approach 2:
The invention creates a composite antimicrobial agent that combines features of both gram-positive and gram-negative targeted bacteriocins through sequence modification. The modified amino acid sequence acts as a composite structure that can interact with diverse bacterial cell wall compositions, achieving broad-spectrum activity while maintaining specificity for gram-positive bacteria.
2Measurement precision
If bacteriocins are used to target specific bacteria, then high specificity is achieved, but broad antimicrobial spectrum is lost
Solution Approach 1:
The patent engineers bacteriocins with multi-functional capabilities by modifying their amino acid sequences to recognize multiple types of bacterial cell wall structures. The modified bacteriocin can simultaneously target gram-positive bacteria with high specificity while also being capable of acting against gram-negative bacteria, achieving both specificity and broad spectrum activity.
Solution Approach 2:
The invention applies local quality changes by modifying specific regions of the bacteriocin molecule (such as the N-terminal or C-terminal regions) while preserving other critical functional regions. This localized modification allows the bacteriocin to gain ability to interact with diverse bacterial targets without losing its specific recognition capabilities for gram-positive bacteria.
Data Source
AI summary
A consumable product having an anti-gram-negative bacterial compound with the amino acid sequence represented by the chemical formula below. Also described is a consumable product having Bacillus subtilis capable of producing a compound having the sequence represented by the chemical formula below. The Bacillus subtilis may be Bacillus subtilis MT2 strain (accession number: NITE BP-02767). Also described are methods of treating enteritis by administering a product as described herein to a patent in need thereof.